| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9027 | Clofarabine | Clolar | 1 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 2004 | Jan 1, 2006 | In Use | ||
| J9074 | Cyclophosphamide (sandoz) | Cyclophosphamide (sandoz) | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2014 | Apr 17, 2024 | In Use | ||
| J9230 | Mechlorethamine | Mustargen | 10 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1949 | Jan 1, 1986 | In Use | ||
| NA | Estrogens, Esterified | Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est | 1.25 mg | Hormonal Therapy | Estrogen | Yes | 1977 | In Use | ||||
| J9198 | Gemcitabine HCl | Infugem | 100mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2018 | Jul 1, 2020 | In Use | ||
| J1010 | Methylprednisolone acetate | Methylprednisolone acetate | 1mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Apr 17, 2024 | In Use | ||
| NA | Nintedanib | Ofev | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use | |||
| J9281 | Mitomycin Pyelocalyceal Instillation | Jelmyto | 1mg | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/Mitomycin | No | 2020 | Jan 1, 2021 | In Use | ||
| NA | Bosutinib | Bosulif | 500 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2012 | In Use | |||
| J9262 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Jan 1, 2014 | In Use | ||
| C9257 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jan 1, 2010 | In Use | ||
| NA | Finasteride | Proscar | 5mg | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Yes | 1992 | In Use | |||
| NA | Metoclopramide | Reglan | 5mg, 10mg | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Yes | 1991 | In Use | |||
| J9267 | Paclitaxel | Taxol | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1992 | Jan 1, 2015 | In Use | ||
| J9311 | Rituximab and Hyaluronidase | Rituxan Hycela | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2017 | Jan 1, 2019 | In Use | ||
| NA | Palbociclib | Ibrance | 125 mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Yes | 2015 | In Use | |||
| J2468 | Palonosetron hydrochloride (avyxa) | Palonosetron hydrochloride (avyxa) | 25 MCG | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 2016 | Jun 10, 2024 | In Use | ||
| Tovorafenib | Ojemda | 25mg, 100mg | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | Yes | 2024 | In Use | ||||
| J1456 | Fosaprepitant (Teva) | Fosaprepitant (Teva) | 1mg | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | No | 2019 | Dec 21, 2022 | In Use | ||
| J8565 | Gefitinib | Iressa | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2015 | Jan 1, 2005 | In Use | ||
| Q5115 | Rituximab-abbs | Truxima | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2018 | Jul 1, 2019 | In Use | ||
| NA | Binimetinib | Mektovi | 15mg | Chemotherapy | MEK Inhibitor | MEK 1/2 | Yes | 2018 | In Use | |||
| NA | Pilocarpine Hydrochloride | Pilocarpine | 5mg, 10mg | Ancillary Therapy | Miscellaneous Agent | Cholinergic Agent | Yes | 2020 | In Use | |||
| J0881 | Darbepoetin alfa | Aranesp | 1 mcg | Ancillary Therapy | Erythropoiesis-Stimulating Agent | No | 2001 | Jan 1, 2006 | In Use | |||
| J9264 | Paclitaxel | Abraxane, protein bound | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1992 | Jan 1, 2006 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home